Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr Strickler on the Significance of Fruquintinib for Patients With Refractory mCRC

August 28th 2024

John H. Strickler, MD, discusses the significance of fruquintinib for patients with metastatic colorectal cancer who have exhausted standard therapies.

Dr Cecchini on Etrumadenant-Based Combinations in Previously Treated mCRC

August 26th 2024

Michael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

August 21st 2024

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

Dr Parikh on the Rationale for Adding ERAS-007 to the BEACON Regimen in BRAF V600E–Mutant mCRC

August 21st 2024

Aparna Parikh, MD, discusses the rationale for adding ERAS-007 to the BEACON regimen in BRAF V600E–mutated metastatic colorectal cancer.

Adagrasib/Cetuximab Combo Marks the Beginning of the RAS-Targeting Era in CRC

August 19th 2024

Rona Yaeger, MD, details the FDA approval of adagrasib plus cetuximab in KRAS G12C-mutated colorectal cancer and how the approval will advance the field.

Dr Kim on Current Unmet Needs in the Management of Resectable CRC

August 16th 2024

Richard Kim, MD, discusses the current treatment paradigm for patients with resectable CRC, as well as unmet needs in this population.

Dr Christenson on the Safety of Copanlisib Plus Nivolumab in Pretreated MSS mCRC

August 15th 2024

Eric S. Christenson, MD, discusses the safety of copanlisib plus nivolumab in pretreated, PIK3Ca-mutated microsatellite stable, unresectable or metastatic colorectal cancer.

Dr Adam on Efforts to Reduce Recurrence Risk in CRC Liver Metastases

August 15th 2024

Rene Adam, MD, PhD, discusses future research aimed at reducing the risk of recurrence in patients with unresectable colorectal liver metastases

Dr Cremolini on the Implications of the TRANSMET Trial in Colorectal Liver Metastases

August 15th 2024

Chiara Cremolini, MD, PhD, discusses the implications of the TRANSMET trial in patients with unresectable colorectal liver metastases.

Dr Bekaii-Saab on the Final Analysis of MOUNTAINEER in HER2+ CRC

August 8th 2024

Tanios Bekaii-Saab, MD, FACP, discusses final results from the MOUNTAINEER trial in HER2+ metastatic colorectal cancer.

Guardant Reveal Test Is Effective in Predicting Recurrence in Stage II and Higher CRC

August 7th 2024

The Guardant Reveal test was accurate in predicting disease recurrence in stage II or higher colorectal cancer.

ABBV-400 Demonstrates Preliminary Efficacy, Safety in MSS/pMMR Advanced CRC

August 1st 2024

ABBV-400 displayed efficacy and tolerability in microsatellite stable/mismatch repair–proficient advanced colorectal cancer.

Bevacizumab Biosimilar Receives Approval in the European Union

July 30th 2024

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

Shield Blood Test Receives FDA Approval for CRC Screening in Adults

July 29th 2024

The Shield blood test has been approved by the FDA for CRC screening in adults aged 45 years and older who are at average risk for the disease.

Exploring Unmet Needs to Optimize Neoadjuvant Therapy in Resectable CRC

July 19th 2024

Richard Kim, MD, discusses the standard treatment approaches and unmet needs for patients with resectable colorectal cancer.

FDA Advises Against Accelerated Approval Pathway for Botensilimab/Balstilimab in R/R MSS CRC

July 18th 2024

The FDA completed an end-of-phase 2 meeting for botensilimab plus balstilimab in relapsed/refractory microsatellite stable colorectal cancer.

Longest OS Reported From a Third-Line mCRC Randomized Trial Is Seen in ARC-9 Study

July 18th 2024

Tanios S. Bekaii-Saab, MD, highlights data from the phase 1/2 ARC-9 study which showed promising overall survival data in patients with colorectal cancer.

Dr Chao on the Correlation Between Broad-Spectrum Antibiotics and Early-Onset CRC

July 11th 2024

Chun Chao, PhD, MS, discusses the association between the use of broad-spectrum antibiotics and the risk of developing early-onset colorectal cancer.

Efficacy and Safety of Fruquintinib in Patients With Metastatic Colorectal Cancer According to Prior Treatment Sequence in the Refractory Setting: Results From FRESCO and FRESCO-2

July 5th 2024

A phase 3, randomized, double-blind, placebo-controlled study to determine if prior TAS-102 and/or regorafenib treatment status and sequence affect the efficacy and safety of fruquintinib in patients with mCRC. This study used data from both FRESCO (NCT02314819) and FRESCO-2 (NCT04322539).

OncLive’s June Roundup of Key FDA Approvals in Oncology

July 3rd 2024

Here is your guide to the important regulatory decisions made by the FDA in June 2024.